However, the utility of circulating tumor-specific biomarkers, such as carbohydrate antigen-125 (CA-125) and carcinoembryonic antigen (CEA), is still limited in the diagnosis and follow-up of ccRCC. This evidence concerns the gene CEACAM5 and nonpapillary renal cell carcinoma.